Real Time Insider Transaction Data
Real Time Insider buys and sells Data - Insider Trades - Insider Transactions - Insider Trading Data - SEC Form 4 Data
Total | Transactions | Amount |
Buys | 1 | $13,723 |
Sells | 133 | $89,472,443 |
Security | Reporting Name | Relationship | Purchase/Sale | Shares | Price $ | D/I | ||||
08 Mar 2024 19:52 | ELVN | Enliven Therapeutics Inc | PATEL ANISH | CHIEF OPERATING OFFICER | 06 Mar 2024 | Sale | 4,875 | 15.6387 | 76,239 | D |
04 Mar 2024 17:55 | ELVN | Enliven Therapeutics Inc | LYSSIKATOS JOSEPH P | CHIEF SCIENTIFIC OFFICER | 29 Feb 2024 | Sale | 1,805 | 17.0938 | 30,854 | D |
04 Mar 2024 17:55 | ELVN | Enliven Therapeutics Inc | LYSSIKATOS JOSEPH P | CHIEF SCIENTIFIC OFFICER | 29 Feb 2024 | Sale | 10,195 | 16.2974 | 166,152 | D |
29 Feb 2024 17:27 | ELVN | Enliven Therapeutics Inc | HOHL BENJAMIN | CHIEF FINANCIAL OFFICER | 27 Feb 2024 | Sale | 3,250 | 16.9732 | 55,163 | D |
28 Feb 2024 17:14 | ELVN | Enliven Therapeutics Inc | KINTZ SAMUEL | PRESIDENT AND CEO | 26 Feb 2024 | Sale | 4,376 | 17.2383 | 75,435 | D |
28 Feb 2024 17:14 | ELVN | Enliven Therapeutics Inc | KINTZ SAMUEL | PRESIDENT AND CEO | 26 Feb 2024 | Sale | 7,624 | 16.6866 | 127,219 | D |
20 Feb 2024 19:41 | ELVN | Enliven Therapeutics Inc | HEYMAN RICHARD A. | Director | 15 Feb 2024 | Sale | 1,270 | 17.4153 | 22,117 | D |
16 Feb 2024 16:15 | ELVN | Enliven Therapeutics Inc | 5AM PARTNERS VI, LLC | 10% | 14 Feb 2024 | Sale | 136,642 | 14.9 | 2,035,966 | I |
16 Feb 2024 16:15 | ELVN | Enliven Therapeutics Inc | 5AM PARTNERS VI, LLC | 10% | 14 Feb 2024 | Sale | 688,358 | 14.9 | 10,256,534 | I |
08 Feb 2024 20:47 | ELVN | Enliven Therapeutics Inc | PATEL ANISH | CHIEF OPERATING OFFICER | 06 Feb 2024 | Sale | 4,875 | 15.1094 | 73,658 | D |
02 Feb 2024 16:29 | ELVN | Enliven Therapeutics Inc | 5AM PARTNERS VI, LLC | 10% | 31 Jan 2024 | Sale | 82,813 | 15 | 1,242,195 | I |
02 Feb 2024 16:29 | ELVN | Enliven Therapeutics Inc | 5AM PARTNERS VI, LLC | 10% | 31 Jan 2024 | Sale | 417,187 | 15 | 6,257,805 | I |
01 Feb 2024 20:10 | ELVN | Enliven Therapeutics Inc | HEYMAN RICHARD A. | Director | 30 Jan 2024 | Sale | 1,270 | 16.4091 | 20,840 | D |
31 Jan 2024 21:20 | ELVN | Enliven Therapeutics Inc | HOHL BENJAMIN | CHIEF FINANCIAL OFFICER | 29 Jan 2024 | Sale | 3,250 | 15.8118 | 51,388 | D |
31 Jan 2024 21:22 | ELVN | Enliven Therapeutics Inc | LYSSIKATOS JOSEPH P | CHIEF SCIENTIFIC OFFICER | 29 Jan 2024 | Sale | 12,000 | 15.8547 | 190,256 | D |
29 Jan 2024 20:01 | ELVN | Enliven Therapeutics Inc | KINTZ SAMUEL | President and CEO | 25 Jan 2024 | Sale | 9,458 | 15.8868 | 150,257 | D |
29 Jan 2024 20:01 | ELVN | Enliven Therapeutics Inc | KINTZ SAMUEL | President and CEO | 25 Jan 2024 | Sale | 2,542 | 14.9379 | 37,972 | D |
24 Jan 2024 18:38 | ELVN | Enliven Therapeutics Inc | PATEL ANISH | Chief Operating Officer | 22 Jan 2024 | Sale | 4,875 | 15.135 | 73,783 | D |
03 Jan 2024 19:01 | ELVN | Enliven Therapeutics Inc | LYSSIKATOS JOSEPH P | Chief Scientific Officer | 29 Dec 2023 | Sale | 2,849 | 14.7818 | 42,113 | D |
03 Jan 2024 19:01 | ELVN | Enliven Therapeutics Inc | LYSSIKATOS JOSEPH P | Chief Scientific Officer | 29 Dec 2023 | Sale | 9,151 | 14.1261 | 129,268 | D |
02 Jan 2024 19:59 | ELVN | Enliven Therapeutics Inc | HOHL BENJAMIN | Chief Financial Officer | 02 Jan 2024 | Sale | 9,383 | 15.01 | 140,839 | D |
02 Jan 2024 19:59 | ELVN | Enliven Therapeutics Inc | HOHL BENJAMIN | Chief Financial Officer | 29 Dec 2023 | Sale | 20 | 15 | 300 | D |
02 Jan 2024 19:59 | ELVN | Enliven Therapeutics Inc | HOHL BENJAMIN | Chief Financial Officer | 28 Dec 2023 | Sale | 2,467 | 15.0742 | 37,188 | D |
02 Jan 2024 20:00 | ELVN | Enliven Therapeutics Inc | PATEL ANISH | Chief Operating Officer | 02 Jan 2024 | Sale | 11,000 | 15.0048 | 165,053 | D |
02 Jan 2024 20:00 | ELVN | Enliven Therapeutics Inc | PATEL ANISH | Chief Operating Officer | 29 Dec 2023 | Sale | 20 | 15 | 300 | D |
02 Jan 2024 20:00 | ELVN | Enliven Therapeutics Inc | PATEL ANISH | Chief Operating Officer | 28 Dec 2023 | Sale | 2,520 | 15.0776 | 37,996 | D |
28 Dec 2023 16:29 | ELVN | Enliven Therapeutics Inc | KINTZ SAMUEL | President and CEO | 26 Dec 2023 | Sale | 12,000 | 14.6424 | 175,709 | D |
27 Dec 2023 17:26 | ELVN | Enliven Therapeutics Inc | HOHL BENJAMIN | Chief Financial Officer | 22 Dec 2023 | Sale | 1,030 | 15.0728 | 15,525 | D |
27 Dec 2023 17:26 | ELVN | Enliven Therapeutics Inc | HOHL BENJAMIN | Chief Financial Officer | 26 Dec 2023 | Sale | 100 | 15 | 1,500 | D |
27 Dec 2023 17:28 | ELVN | Enliven Therapeutics Inc | PATEL ANISH | Chief Operating Officer | 26 Dec 2023 | Sale | 102 | 15.005 | 1,531 | D |
27 Dec 2023 17:28 | ELVN | Enliven Therapeutics Inc | PATEL ANISH | Chief Operating Officer | 22 Dec 2023 | Sale | 983 | 15.0313 | 14,776 | D |
26 Dec 2023 19:31 | ELVN | Enliven Therapeutics Inc | KINTZ SAMUEL | President and CEO | 22 Dec 2023 | Sale | 8,175 | 13.0465 | 106,655 | D |
26 Dec 2023 19:31 | ELVN | Enliven Therapeutics Inc | KINTZ SAMUEL | President and CEO | 21 Dec 2023 | Sale | 20 | 13 | 260 | D |
26 Dec 2023 19:32 | ELVN | Enliven Therapeutics Inc | LYSSIKATOS JOSEPH P | Chief Scientific Officer | 22 Dec 2023 | Sale | 6,546 | 13.066 | 85,530 | D |
26 Dec 2023 19:32 | ELVN | Enliven Therapeutics Inc | LYSSIKATOS JOSEPH P | Chief Scientific Officer | 21 Dec 2023 | Sale | 20 | 13 | 260 | D |
26 Dec 2023 19:29 | ELVN | Enliven Therapeutics Inc | HEYMAN RICHARD A. | Director | 22 Dec 2023 | Sale | 168 | 13 | 2,184 | D |
26 Dec 2023 19:29 | ELVN | Enliven Therapeutics Inc | HEYMAN RICHARD A. | Director | 22 Dec 2023 | Sale | 35 | 13 | 455 | I |
26 Dec 2023 19:29 | ELVN | Enliven Therapeutics Inc | HEYMAN RICHARD A. | Director | 21 Dec 2023 | Sale | 6 | 13 | 78 | I |
26 Dec 2023 19:29 | ELVN | Enliven Therapeutics Inc | HEYMAN RICHARD A. | Director | 21 Dec 2023 | Sale | 7 | 13 | 91 | D |
21 Dec 2023 16:29 | ELVN | Enliven Therapeutics Inc | LYSSIKATOS JOSEPH P | Chief Scientific Officer | 20 Dec 2023 | Sale | 8,688 | 13.0117 | 113,046 | D |
21 Dec 2023 16:29 | ELVN | Enliven Therapeutics Inc | LYSSIKATOS JOSEPH P | Chief Scientific Officer | 19 Dec 2023 | Sale | 200 | 13 | 2,600 | D |
21 Dec 2023 16:31 | ELVN | Enliven Therapeutics Inc | KINTZ SAMUEL | President and CEO | 20 Dec 2023 | Sale | 7,779 | 13.0143 | 101,238 | D |
21 Dec 2023 16:28 | ELVN | Enliven Therapeutics Inc | HEYMAN RICHARD A. | Director | 20 Dec 2023 | Sale | 1,915 | 13.0232 | 24,939 | I |
21 Dec 2023 16:28 | ELVN | Enliven Therapeutics Inc | HEYMAN RICHARD A. | Director | 19 Dec 2023 | Sale | 255 | 13 | 3,315 | D |
21 Dec 2023 16:28 | ELVN | Enliven Therapeutics Inc | HEYMAN RICHARD A. | Director | 20 Dec 2023 | Sale | 2,110 | 13.0202 | 27,473 | D |
06 Nov 2023 16:42 | ELVN | Enliven Therapeutics Inc | KINTZ SAMUEL | President and CEO | 03 Nov 2023 | Sale | 8,026 | 13.0824 | 104,999 | D |
06 Nov 2023 16:43 | ELVN | Enliven Therapeutics Inc | LYSSIKATOS JOSEPH P | Chief Scientific Officer | 03 Nov 2023 | Sale | 8,546 | 13.0764 | 111,751 | D |
03 Oct 2023 19:40 | ELVN | Enliven Therapeutics Inc | LYSSIKATOS JOSEPH P | Chief Scientific Officer | 29 Sep 2023 | Sale | 12,000 | 13.6248 | 163,498 | D |
28 Sep 2023 16:27 | ELVN | Enliven Therapeutics Inc | 5AM PARTNERS VI, LLC | 10% | 26 Sep 2023 | Sale | 32,711 | 15 | 490,665 | I |
28 Sep 2023 16:27 | ELVN | Enliven Therapeutics Inc | 5AM PARTNERS VI, LLC | 10% | 26 Sep 2023 | Sale | 164,789 | 15 | 2,471,835 | I |
26 Sep 2023 19:37 | ELVN | Enliven Therapeutics Inc | KINTZ SAMUEL | President and CEO | 25 Sep 2023 | Sale | 12,000 | 13.8076 | 165,691 | D |
18 Sep 2024 16:17 | ELVN | Enliven Therapeutics Inc | HEYMAN RICHARD A. | Director | 16 Sep 2024 | Sale | 1,270 | 22.408 | 28,458 | D |
03 Sep 2024 17:43 | ELVN | Enliven Therapeutics Inc | LYSSIKATOS JOSEPH P | CHIEF SCIENTIFIC OFFICER | 29 Aug 2024 | Sale | 50 | 23.08 | 1,154 | I |
03 Sep 2024 17:43 | ELVN | Enliven Therapeutics Inc | LYSSIKATOS JOSEPH P | CHIEF SCIENTIFIC OFFICER | 29 Aug 2024 | Sale | 11,950 | 22.4843 | 268,687 | I |
29 Aug 2024 18:36 | ELVN | Enliven Therapeutics Inc | HOHL BENJAMIN | CHIEF FINANCIAL OFFICER | 27 Aug 2024 | Sale | 4,250 | 22.5369 | 95,782 | D |
28 Aug 2024 19:48 | ELVN | Enliven Therapeutics Inc | KINTZ SAMUEL | PRESIDENT AND CEO | 26 Aug 2024 | Sale | 12,000 | 22.8932 | 274,718 | I |
19 Aug 2024 19:49 | ELVN | Enliven Therapeutics Inc | HEYMAN RICHARD A. | Director | 15 Aug 2024 | Sale | 620 | 23.7027 | 14,696 | D |
19 Aug 2024 19:49 | ELVN | Enliven Therapeutics Inc | HEYMAN RICHARD A. | Director | 15 Aug 2024 | Sale | 650 | 22.8162 | 14,831 | D |
02 Aug 2024 19:26 | ELVN | Enliven Therapeutics Inc | LYSSIKATOS JOSEPH P | CHIEF SCIENTIFIC OFFICER | 31 Jul 2024 | Sale | 3,099 | 27.5571 | 85,399 | I |
02 Aug 2024 19:25 | ELVN | Enliven Therapeutics Inc | KINTZ SAMUEL | PRESIDENT AND CEO | 31 Jul 2024 | Sale | 2,270 | 27.5573 | 62,555 | I |
02 Aug 2024 19:22 | ELVN | Enliven Therapeutics Inc | HEYMAN RICHARD A. | Director | 31 Jul 2024 | Sale | 1,702 | 27.5059 | 46,815 | D |
02 Aug 2024 19:22 | ELVN | Enliven Therapeutics Inc | HEYMAN RICHARD A. | Director | 31 Jul 2024 | Sale | 649 | 27.5 | 17,848 | I |
02 Aug 2024 19:23 | ELVN | Enliven Therapeutics Inc | HOHL BENJAMIN | CHIEF FINANCIAL OFFICER | 31 Jul 2024 | Sale | 991 | 27.5287 | 27,281 | D |
31 Jul 2024 19:31 | ELVN | Enliven Therapeutics Inc | HOHL BENJAMIN | CHIEF FINANCIAL OFFICER | 29 Jul 2024 | Sale | 61 | 27.4431 | 1,674 | D |
31 Jul 2024 19:31 | ELVN | Enliven Therapeutics Inc | HOHL BENJAMIN | CHIEF FINANCIAL OFFICER | 29 Jul 2024 | Sale | 5,189 | 26.6676 | 138,378 | D |
31 Jul 2024 19:33 | ELVN | Enliven Therapeutics Inc | LYSSIKATOS JOSEPH P | CHIEF SCIENTIFIC OFFICER | 29 Jul 2024 | Sale | 203 | 27.4333 | 5,569 | I |
31 Jul 2024 19:33 | ELVN | Enliven Therapeutics Inc | LYSSIKATOS JOSEPH P | CHIEF SCIENTIFIC OFFICER | 29 Jul 2024 | Sale | 11,797 | 26.6855 | 314,809 | I |
29 Jul 2024 17:39 | ELVN | Enliven Therapeutics Inc | KINTZ SAMUEL | PRESIDENT AND CEO | 25 Jul 2024 | Sale | 43 | 25.8295 | 1,111 | I |
29 Jul 2024 17:39 | ELVN | Enliven Therapeutics Inc | KINTZ SAMUEL | PRESIDENT AND CEO | 25 Jul 2024 | Sale | 8,164 | 25.1004 | 204,920 | I |
29 Jul 2024 17:39 | ELVN | Enliven Therapeutics Inc | KINTZ SAMUEL | PRESIDENT AND CEO | 25 Jul 2024 | Sale | 3,793 | 24.53 | 93,042 | I |
17 Jul 2024 19:25 | ELVN | Enliven Therapeutics Inc | HEYMAN RICHARD A. | Director | 15 Jul 2024 | Sale | 1,270 | 24.8006 | 31,497 | D |
16 Jul 2024 17:34 | ELVN | Enliven Therapeutics Inc | HOHL BENJAMIN | CHIEF FINANCIAL OFFICER | 12 Jul 2024 | Sale | 3,000 | 25.065 | 75,195 | D |
16 Jul 2024 17:37 | ELVN | Enliven Therapeutics Inc | PATEL ANISH | CHIEF OPERATING OFFICER | 16 Jul 2024 | Sale | 1,547 | 25.0111 | 38,692 | I |
16 Jul 2024 17:37 | ELVN | Enliven Therapeutics Inc | PATEL ANISH | CHIEF OPERATING OFFICER | 15 Jul 2024 | Sale | 30,978 | 25.0513 | 776,039 | I |
16 Jul 2024 17:37 | ELVN | Enliven Therapeutics Inc | PATEL ANISH | CHIEF OPERATING OFFICER | 12 Jul 2024 | Sale | 17,475 | 25.0698 | 438,095 | I |
03 Jul 2024 16:31 | ELVN | Enliven Therapeutics Inc | LYSSIKATOS JOSEPH P | CHIEF SCIENTIFIC OFFICER | 01 Jul 2024 | Sale | 12,000 | 22.8947 | 274,736 | I |
01 Jul 2024 20:03 | ELVN | Enliven Therapeutics Inc | HOHL BENJAMIN | CHIEF FINANCIAL OFFICER | 27 Jun 2024 | Sale | 1,140 | 23.4308 | 26,711 | D |
01 Jul 2024 20:03 | ELVN | Enliven Therapeutics Inc | HOHL BENJAMIN | CHIEF FINANCIAL OFFICER | 27 Jun 2024 | Sale | 1,830 | 22.5756 | 41,313 | D |
01 Jul 2024 20:03 | ELVN | Enliven Therapeutics Inc | HOHL BENJAMIN | CHIEF FINANCIAL OFFICER | 27 Jun 2024 | Sale | 1,280 | 21.7946 | 27,897 | D |
27 Jun 2024 16:35 | ELVN | Enliven Therapeutics Inc | KINTZ SAMUEL | PRESIDENT AND CEO | 25 Jun 2024 | Sale | 578 | 22.296 | 12,887 | I |
27 Jun 2024 16:35 | ELVN | Enliven Therapeutics Inc | KINTZ SAMUEL | PRESIDENT AND CEO | 25 Jun 2024 | Sale | 11,422 | 21.6262 | 247,014 | I |
20 Jun 2024 19:20 | ELVN | Enliven Therapeutics Inc | HEYMAN RICHARD A. | Director | 17 Jun 2024 | Sale | 1,270 | 21.4787 | 27,278 | D |
10 Jun 2024 18:46 | ELVN | Enliven Therapeutics Inc | PATEL ANISH | CHIEF OPERATING OFFICER | 06 Jun 2024 | Sale | 1,133 | 20.0551 | 22,722 | D |
31 May 2024 16:05 | ELVN | Enliven Therapeutics Inc | LYSSIKATOS JOSEPH P | CHIEF SCIENTIFIC OFFICER | 29 May 2024 | Sale | 2,123 | 22.5212 | 47,813 | D |
31 May 2024 16:05 | ELVN | Enliven Therapeutics Inc | LYSSIKATOS JOSEPH P | CHIEF SCIENTIFIC OFFICER | 29 May 2024 | Sale | 9,877 | 21.564 | 212,988 | D |
30 May 2024 17:56 | ELVN | Enliven Therapeutics Inc | KINTZ SAMUEL | PRESIDENT AND CEO | 28 May 2024 | Sale | 100 | 24.34 | 2,434 | D |
30 May 2024 17:56 | ELVN | Enliven Therapeutics Inc | KINTZ SAMUEL | PRESIDENT AND CEO | 28 May 2024 | Sale | 5,219 | 23.5715 | 123,020 | D |
30 May 2024 17:56 | ELVN | Enliven Therapeutics Inc | KINTZ SAMUEL | PRESIDENT AND CEO | 28 May 2024 | Sale | 6,681 | 22.8643 | 152,756 | D |
30 May 2024 17:54 | ELVN | Enliven Therapeutics Inc | HOHL BENJAMIN | CHIEF FINANCIAL OFFICER | 28 May 2024 | Sale | 10 | 24.34 | 243 | D |
30 May 2024 17:54 | ELVN | Enliven Therapeutics Inc | HOHL BENJAMIN | CHIEF FINANCIAL OFFICER | 28 May 2024 | Sale | 2,334 | 23.4184 | 54,659 | D |
30 May 2024 17:54 | ELVN | Enliven Therapeutics Inc | HOHL BENJAMIN | CHIEF FINANCIAL OFFICER | 28 May 2024 | Sale | 1,906 | 22.89 | 43,628 | D |
20 May 2024 19:46 | ELVN | Enliven Therapeutics Inc | HEYMAN RICHARD A. | Director | 16 May 2024 | Sale | 1,270 | 23.7399 | 30,150 | D |
20 May 2024 17:00 | ELVN | Enliven Therapeutics Inc | ORBIMED ADVISORS LLC | Director , 10% | 16 May 2024 | Sale | 1,000,000 | 22.14 | 22,140,000 | I |
20 May 2024 17:00 | ELVN | Enliven Therapeutics Inc | ORBIMED ADVISORS LLC | Director , 10% | 16 May 2024 | Sale | 33,300 | 22.14 | 737,262 | I |
20 May 2024 17:03 | ELVN | Enliven Therapeutics Inc | GUPTA RISHI | Director , 10% | 16 May 2024 | Sale | 1,000,000 | 22.14 | 22,140,000 | I |
20 May 2024 17:03 | ELVN | Enliven Therapeutics Inc | GUPTA RISHI | Director , 10% | 16 May 2024 | Sale | 33,300 | 22.14 | 737,262 | I |
16 May 2024 19:29 | ELVN | Enliven Therapeutics Inc | PATEL ANISH | CHIEF OPERATING OFFICER | 14 May 2024 | Sale | 1,107 | 25 | 27,675 | D |
13 May 2024 19:35 | ELVN | Enliven Therapeutics Inc | PATEL ANISH | CHIEF OPERATING OFFICER | 09 May 2024 | Sale | 260 | 25.0596 | 6,515 | D |
08 May 2024 20:40 | ELVN | Enliven Therapeutics Inc | PATEL ANISH | CHIEF OPERATING OFFICER | 06 May 2024 | Sale | 4,875 | 22.7219 | 110,769 | D |
07 May 2024 18:58 | ELVN | Enliven Therapeutics Inc | HOHL BENJAMIN | CHIEF FINANCIAL OFFICER | 03 May 2024 | Sale | 1,000 | 22.5 | 22,500 | D |
* D/I = Direct / Indirect
* 10% = Entity with 10% or higher ownership stake
* A = Amendment Filing (SEC Form 4/A)